Lycored Ltd.

Ben-Gurion University of the Negev Research and Development Authority

Mor Research Applications Ltd.

Rachel Levy

Morris Zelkha

Tanya Sedlov

Nurit Hadad

Masha Sapojnik

Yoav Blatt

Yoav Sharoni

Joseph Levy

Tatyana Atlasman

Esther Paran

The present invention provides a therapeutic composition comprising heat-treated clear tomato concentrate (CTC), which has been found to possess both anti-inflammatory and bone-health promoting effects. The present invention is also directed to a composition comprising heat-treated CTC in combination with one or more carotenoids.

Compositions comprising heat-treated clear tomato concentrate

Compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. Compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.

Astaxanthin anti-inflammatory synergistic combinations

This invention is directed to compositions having synergistic combinations of omega-3 fatty acid such as OMEGA-3 with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.

Anti-inflammatory omega-3 synergistic combinations

This invention is directed to compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.

Inhibitors of cPLA&#x3b1; expression are used in the preparation of pharmaceutical compositions for the inhibition of cancer cell proliferation and for the treatment of cancer; the inhibitors are selected from cPLA&#x3b1;-specific ribozymes, RNA sequences usable for RNA-interference of the cPLA&#x3b1; gene, and antisense oligonucleotides directed against cPLA&#x3b1;.

Use of antisense oligonucleotides against CPLA2 in the treatment of cancer

Antisense oligonucleotides against cPLAare provided, which are capable of inhibiting cPLAexpression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases. The antisense oligonucleotides or compositions comprising the same may be used in methods of treatment of such diseases.

Growing community of inventors

Omer, Israel

Rachel Levy